The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta-Analysis.
Combining immune drugs with radiation and chemotherapy may improve survival for patients with advanced cancers.
This Int J Cancer systematic review and meta-analysis evaluates whether adding concurrent immune checkpoint inhibitors to chemoradiotherapy (with consolidative ICI) improves outcomes across unresectable cancers. The meta-analysis provides actionable evidence for treatment sequencing and combination decisions in current oncology practice.
What the study was
- Study design
- Systematic Review and Meta-Analysis
- Population
- Patients with unresectable cancers receiving chemoradiotherapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International Journal of Cancer
Why it surfaced
Meta-analysis addressing a current clinical question (concurrent vs. consolidative ICI) across multiple unresectable cancers. Directly practice-relevant for oncologists managing NSCLC, head/neck, esophageal, and other cancers with CRT+ICI regimens.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.